NOVARTIS N - Dusseldorf Stock Exchang (NOT DU) stock market data APIs
€115.1296
0.08(0.1%)
as of December 18, 2025
Try our APIs with
free plan!
NOVARTIS N - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.DU.
Prev. Close
115.1296
Open
115.2874
High
115.3871
Low
115.0363
52 wk Range
71.5574-116.26
Market Cap
160 075 M
Dividends (Yield)
0.0487
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N - Dusseldorf Stock Exchang data using free add-ons & libraries
Get NOVARTIS N - Dusseldorf Stock Exchang Fundamental Data
NOVARTIS N - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get NOVARTIS N - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N - Dusseldorf Stock Exchang News
New
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated ...
Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials
Viatris (VTRS) said Thursday the US Food and Drug Administration approved octreotide acetate for inj PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally
SAN FRANCISCO, December 17, 2025--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative medicines company, has select...
HSBC Lifts PT on Novartis AG (NVS) to $112 From $106
Novartis AG (NYSE:NVS) is one of the most profitable NYSE stocks to buy right now. HSBC lifted the price target on Novartis AG (NYSE:NVS) to $112 from $106 on December 10 while maintaining a Reduce ra...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
